Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) shares shot up 4.4% during trading on Thursday . The company traded as high as $8.82 and last traded at $8.25, with a volume of 171,160 shares. The stock had previously closed at $7.90.

A number of brokerages have commented on ORMP. FBR & Co raised their price target on shares of Oramed Pharmaceuticals from $15.00 to $20.00 and gave the stock an “outperform” rating in a research note on Thursday, May 26th. Aegis restated a “buy” rating and set a $18.00 price target on shares of Oramed Pharmaceuticals in a research note on Wednesday, May 18th. Finally, Rodman & Renshaw restated a “buy” rating and set a $25.00 price target on shares of Oramed Pharmaceuticals in a research note on Friday, May 13th. Five research analysts have rated the stock with a buy rating, Oramed Pharmaceuticals has a consensus rating of “Buy” and an average price target of $22.00.

The stock’s 50-day moving average price is $8.16 and its 200-day moving average price is $7.69. The stock’s market capitalization is $107.32 million.

Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.